Navigation Links
Pharma Industry Unites With Academia to Tackle Ongoing Problem

LONDON, October 28, 2011 /PRNewswire/ --

Leading academic and industry specialists to meet in Amsterdam next February to discuss the challenges that could see R&D grind to a halt and the newest ways to tackle them

Selecting and screening the correct polymorphs and ensuring the characterisation of the co-crystals in the most efficient and effective way has never been more vital. According to George Tranter from Chiralabs, "Crystallisation is one of the biggest problems of the pharmaceutical industry".

The 8th Annual Polymorphism and Crystallisation speaker panel will be dedicated to presenting the cutting edge technologies and techniques of getting the pharmaceutical product to the market whilst overcoming the problems of polymorphism.

According to an Engineer article "Co-crystallisation could speed up drug production" (5th September), scientists have started seeking to understand the science behind this process. However, co-crystallisation requires particular attention to considerations like availability and quality of drugs, waste streams generated and batch performance. Pharma IQ's Polymorphism and Crystallisation speakers will provide an insight into these issues live only on 28th and 29th February in Amsterdam. Case studies will be presented by the likes of Eli Lily, UCB Pharma and Novartis-MIT Centre for Continuous Manufacturing, and a fantastic interactive workshop will be run by an EPO representative.

Pharma IQ's summit will be dedicated to delivering cutting edge insights into areas such as:

  • Best timing and depth for a polymorphic screen during pharmaceutical development
  • Characterisation of co-crystals and selection of tools for correct characterisation tests
  • Polymorphic scale up
  • Application of PAT and QbD in pharmaceutical processes
  • Patenting of new polymorphs

At Polymorphism and Crystallisation, attendees will hear best practices from the big industry names like GlaxoSmithKline, Merck, AstraZeneca, Johnson and Johnson, Continuous Manufacturing and Crystallisation (CMAC), together with leading academic institutions like University of Loughborough, University of Leeds, University of Rouen, and more.

The full agenda, podcast, articles and interviews, are available on:

The LinkedIn Group is open and welcomes anybody in topic and event related discussions:

Find the full program, event details and registration information on Polymorphism and Crystallisation 2012:
Call: +44(0)207-368-9300

Media contact: Gergana Stoyanova
Tel: +44(0)2073689865

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
2. Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
3. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
4. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
5. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
6. Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate
7. Innovative Pharmacy Leader Jeanne Ann Stasny Joins Diplomat Specialty Pharmacy as Vice President of Pharmacy Services
8. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
9. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
10. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
11. Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):